No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer

byTeddy Guo

January 7, 2021

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract Progression-Free Survival (PFS) was significantly longer with intensive chemotherapy in patients with advanced stage double or triple hit lymphoma (DHL, THL)

RelatedReports

One-year of Herceptin preferable to two-year regimen

Oncology

Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

April 11, 2025

3D mammography (tomosynthesis) enhances accuracy of breast cancer screening

Chronic Disease

Less frequent mammography is non-inferior to annual screening for breast cancer survival in women after curative treatment

April 2, 2025

StudyGraphics

#VisualAbstract Lack of sentinel-lymph node biopsy does not alter survival in early invasive breast cancer

March 27, 2025

Exercise associated with decreased breast cancer risk

Oncology

Lack of sentinel-lymph node biopsy does not alter survival in early invasive breast cancer

March 18, 2025

Glioblastoma phenotypes identified on MRI predict molecular behavior

Carboplatin as a potential adjunct therapy for recurrent high-grade glioma treatment

#VisualAbstract Fondazione Italiana Linfomi (FIL) Phase 3 trial: Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation (HSCT) in mantle cell lymphoma improves progression-free survival (PFS)

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

2 Minute Medicine Rewind January 11, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports